Helix BioPharma (TSE:HBP) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Helix BioPharma has amended its acquisition agreements with Laevoroc Immunology and Laevoroc Chemotherapy to set fixed numbers of common shares issuable, ensuring flexibility for potential financing deals and protecting shareholder value. The adjustments come ahead of a potential financing opportunity that could affect share dilution and valuation. The transactions will require shareholder approval and adherence to stock exchange conditions.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.